0001209191-20-037411.txt : 20200617 0001209191-20-037411.hdr.sgml : 20200617 20200617185152 ACCESSION NUMBER: 0001209191-20-037411 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200615 FILED AS OF DATE: 20200617 DATE AS OF CHANGE: 20200617 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Nicholson Garry A CENTRAL INDEX KEY: 0001640861 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38871 FILM NUMBER: 20970858 MAIL ADDRESS: STREET 1: C/O TESARO, INC. STREET 2: 1000 WINTER STREET, SUITE 3300 CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Turning Point Therapeutics, Inc. CENTRAL INDEX KEY: 0001595893 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 463826166 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10628 SCIENCE CENTER DRIVE, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-926-5251 MAIL ADDRESS: STREET 1: 10628 SCIENCE CENTER DRIVE, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: TP Therapeutics, Inc. DATE OF NAME CHANGE: 20181018 FORMER COMPANY: FORMER CONFORMED NAME: TP Therapeutics, INC DATE OF NAME CHANGE: 20140106 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-06-15 0 0001595893 Turning Point Therapeutics, Inc. TPTX 0001640861 Nicholson Garry A C/O TURNING POINT THERAPEUTICS, INC. 10628 SCIENCE CENTER DRIVE, STE. 200 SAN DIEGO CA 92121 1 0 0 0 Stock Option (right to buy) 59.11 2020-06-15 4 D 0 25000 D 2030-01-21 Common Stock 25000 0 D Stock Option (right to buy) 59.11 2020-06-15 4 A 0 23400 A 2030-01-21 Common Stock 23400 23400 D The reported transaction involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 22, 2020 and provides for vesting of the shares in a series of 36 successive equal monthly installments over the three year period measured from January 22, 2020. /s/ Annette North, Attorney-in-Fact 2020-06-17